[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nuwacell Biotechnologies Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":187},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,69,96,117,141,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100603662","phase-1-a-study-of-89zr-oxine-ncr100-injection-for-the-cellular-distribution-100603662",false,"NCT07139431","A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution","A Study to Evaluate the Cellular Distribution of [89Zr]-Oxine-NCR100 Injection in the Treatment of Subjects With Knee Osteoarthritis","Distribution","Inclusion Criteria:\n\n* Subjects who understand and voluntarily sign the Informed Consent Form（ICF） before enrolment; Age: 40-70 years old, both genders; Men without reproductive intentions; Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria.\n\nSubjects with KOA who have persistent pain for more than six months, Kellgren-Lawrence grade: II-III; McMaster University's Osteoarthritis Index (WOMAC) of the study-side knee joint: 60-180.\n\nExclusion Criteria:\n\n* Subjects previously diagnosed with secondary knee osteoarthritis, or those diagnosed with hip\u002Fankle joint disease requiring medical intervention; Subjects previously diagnosed with secondary knee osteoarthritis, or those diagnosed with hip\u002Fankle joint disease requiring medical intervention; Have received stem cell therapy; Experienced knee surgery, or plan to undergo knee surgery; Have used traditional Chinese medicine to treat KOA within 4 weeks; Have used intra-articular injection of drugs to treat KOA within 12 weeks; Received glucosamine, chondroitin sulfate, or diacetate therapy before investigational drug intervention within 12 weeks; Subjects with the acute phase of knee osteoarthritis; severe deformity of the knee; BMI≥30kg\u002Fm\\^2; Severe systemic infection or local knee joint infection; Have received systemic glucocorticoid therapy before intervention or need to take systemic glucocorticoid therapy during the treatment; Have serious heart disease； Subjects with peripheral or central nervous system disorders that may interfere with assessments; Have contraindications to Magnetic Resonance Imaging(MRI); Subjects with alcohol\u002Fdrug addiction\u002Fabuse or mental disorders; Have participated in other clinical trials within 12 weeks before the screening; Subjects with infection with hepatitis B virus(HBV), hepatitis C virus(HCV), HIV, and Treponema pallidum confirmed by laboratory tests; Subjects with a history of allergic reaction to any component of the trial drug or to acetaminophen; Subjects who are not suitable for PET\u002FCT examination.",true,"MALE","40 Years","70 Years",{"count":22,"type":23},6,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","This clinical study is to evaluate the biodistribution of \\[89Zr\\]-Oxine-NCR100 injection in subjects with knee osteoarthritis after local injection and the kinetic behavior characteristics of zirconium-labeled cells at the injection site and various organs or tissues. It is a single-dose, open-label study in adult KOA subjects.",[29],"KOA",[31],"MSC, KOA","NOT_YET_RECRUITING","2025-08-17",{"date":35,"type":36},"2025-08-24","ACTUAL",{"date":38,"type":23},"2025-08-29",{"date":40,"type":23},"2028-04-21",{"name":42,"class":43},"Nuwacell Biotechnologies Co., Ltd.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":19,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100591322","phase-1-a-trial-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-ncr201-in-the-treatment-of-subjects-with-parkinsons-disease-100591322","NCT06978920","A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease","A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease","Inclusion Criteria:\n\n* Ages between 40 and 75 years;\n* Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;\n* Disease history over 5 years;\n* Stable dose of dopamine treatment;\n* Able to undergo PET\u002FCT\u002FMRI detection;\n\nExclusion Criteria:\n\n* Patients who have previously undergone brain surgery;\n* Past use of stem cell therapy or participation in stem cell clinical research;\n* Cognitive impairment;\n* History of mental disorders;\n* Patients with other serious systemic diseases;\n* Past or current metastatic malignant tumors.","ALL","75 Years",{"count":54,"type":23},48,[26],"The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.",[58],"Parkinson Disease","RECRUITING","2025-07-30",{"date":62,"type":36},"2025-08-01",{"date":64,"type":36},"2025-06-06",{"date":66,"type":23},"2028-12-01",{"name":42,"class":43},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":51,"minAge":76,"maxAge":20,"enrollmentInfo":77,"targetDuration":4,"studyType":24,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100588434","phase-1-a-trial-to-evaluate-the-safety-and-efficacy-of-ncr102-in-subjects-with-agvhd-100588434","NCT06941350","A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD","A Phase I\u002FII Clinical Study Evaluating the Safety and Efficacy of NCR102 Injection in the Treatment of Acute Graft-versus-Host Disease (aGVHD)","Inclusion Criteria:\n\n* Age\\>18 years and \\\u003C70 years old (including threshold), gender not limited；\n* Grade II to IV gastrointestinal involvement acute graft-versus-host disease(aGVHD)；\n* Subjects with Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)；\n* Failed to second-line aGVHD treatment;\n* Subjects will receive NCR102 injection treatment within 3 days after enrollment;\n* Voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* Subjects have lung disease, and investigators have determined that they are not suitable for the study;\n* Subjects with severe hepatic vein occlusion disease or sinus vein occlusion syndrome;\n* Subjects with signs\u002Fsymptoms of chronic GVHD;\n* Subjects who are clinically assessed by the investigator could not be ruled out as having diarrhea caused by cytomegalovirus (CMV) enteritis, transplant related thrombotic microvascular disease (TA-TMA), or digestive tract infection;\n* Eastern Cooperative Oncology Group(ECOG)\\>3；\n* Subjects have other diseases or physiological conditions that may interfere with the evaluation results of this trial, or life-threatening complications；\n* Subjects had active malignant solid tumors within the past 5 years；\n* Subjects had a known history of severe allergies to blood products, or heterologous proteins.","18 Years",{"count":78,"type":23},24,[26,80],"PHASE2","Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.",[83],"Acute Graft-versus-Host Disease",[85,86,87],"SR-aGVHD","NCR102","second-line treatment failure","2025-04-16",{"date":90,"type":36},"2025-04-23",{"date":92,"type":23},"2025-04-28",{"date":94,"type":23},"2027-05-30",{"name":42,"class":43},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":51,"minAge":76,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":24,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100579505","phase-1-a-trial-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-ncr101-in-the-treatment-of-subjects-with-interstitial-lung-disease-100579505","NCT06825169","A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease","A Phase I\u002FII, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (NCR101) Injection in the Treatment of Subjects With Interstitial Lung Disease","Inclusion Criteria:\n\n* Age\\>18 years old (including threshold), gender not limited;\n* Meets the diagnosis of interstitial lung disease;\n* Screening for interstitial lung disease diagnosed by pulmonary imaging within the first 6 months;\n* For patients undergoing glucocorticoid therapy at the time of screening: the background treatment remained stable during the study period;\n* If the patient is undergoing anti-fibrotic therapy (pirfenidone or nintedanib) at the time of screening, they must have received a stable dose for at least 4 weeks at the time of screening and plan to continue receiving this background therapy steadily after entering this study;\n* Patients of childbearing age (male and female) must agree to take effective non pharmacological contraceptive measures during the trial period and within 6 months after the last use of medication:\n* Voluntarily sign an informed consent form and be able to cooperate in completing research related procedures and checks.\n\nExclusion Criteria:\n\n* Individuals with a history of severe allergies or allergies to the main active ingredients or excipients of the investigational drug;\n* Individuals who have been hospitalized for three or more times due to acute exacerbation of ILD or other respiratory diseases within the previous year prior to screening;\n* Individuals with a history of mechanical ventilation (invasive or non-invasive) within the past month prior to screening, or those currently requiring oxygen therapy (oxygen therapy duration\\>15 hours\u002Fday);\n* Individuals who have contracted infectious pneumonia or require intravenous anti-infective treatment within the previous month; Previous history of tuberculosis\n* Patients with other serious respiratory diseases, such as asthma, those with airway obstruction (FEV1\u002FFVC\\\u003C0.7 before using bronchodilators), and those with other clinically significant abnormalities in the lungs;\n* Within the first 3 days of enrollment, use high-dose corticosteroids (equivalent to methylprednisolone\\>240 mg\u002Fday) or irregularly use systemic corticosteroids;",{"count":104,"type":23},30,[26,80],"The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease. The trial contains Single ascending dose（SAD） and Multiple ascending dose（MAD）. Subjects will receive at least 1 dose of NCR101.",[108],"Interstitial Lung Disease (ILD)","2025-02-09",{"date":111,"type":36},"2025-02-13",{"date":113,"type":23},"2025-03-01",{"date":115,"type":23},"2028-09-01",{"name":42,"class":43},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":51,"minAge":19,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100573040","phase-1-a-study-of-ncr100-injection-for-the-treatment-of-knee-osteoarthritis-koa-100573040","NCT06741098","A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）","A Study to Evaluate the Safety, Tolerability and Efficacy of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）","Inclusion Criteria:\n\n* Subjects who understand and voluntarily sign the Informed Consent Form（ICF） before the enrolment;\n* Age: 40-65 years old, both genders;\n* Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria;\n* Subjects with KOA who have persistent pain for more than six months\n* Kellgren-Lawrence grade: II-III\n\nExclusion Criteria:\n\n* Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip\u002Fankle joint disease requiring medical intervention;\n* Suffering from other diseases that impair knee function or joints;\n* Have received stem cell therapy;\n* Have knee injury history;\n* Experienced knee surgery, or plan to undergo knee surgery;\n* Received analgesics to relieve pain before Investigational Medicinal Product(IMP) injections;\n* Have used traditional Chinese medicine to treat KOA within 4 weeks;\n* Have used intra-articular injection of drugs to treat KOA within 12 weeks;\n* Received glucosamine,chondroitin sulfate, or diacetate therapy before investigational drug intervention within 12 weeks;\n* Subjects with acute phase of knee osteoarthritis;\n* Severe deformity of the knee;\n* Known or suspected allergy or a history of allergies;\n* Abnormal results of laboratory examination as follows: Hepatic Insufficiency （Alanine Aminotransferase\\>2xULN or Aspartate aminotransferase \\[ast\\]\\>2xULN) renal dysfunction (creatinine clearance rate ≤60ml\u002Fmin or blood urea nitrogen(BUN) \\> 2× ULN), Coagulation Defects (INR \\> 1.5) or severe hematological diseases (Grade 3 or above anemia \\[Hb \\\u003C 8 g\u002FdL\\], Grade 2 or above thrombocytopenia platelet count(PLT) \\\u003C 75×10\\^9\u002FL) ;\n* BMI≥30kg\u002Fm\\^2\n* Severe systemic infection or local knee joint infection;\n* Have received systemic glucocorticoid therapy before intervention or need to take systemic glucocorticoid therapy during the treatment;\n* Have a history of acute myocardial infarction or severe heart diseases,QT prolongation;\n* Subjects with peripheral or central nervous system disorders that may interfere assessments;\n* Have contraindications to Magnetic Resonance Imaging(MRI)\n* Subjects who are unable to walk on his own;\n* Subjects with alcohol\u002Fdrug addiction\u002Fabuse or mental disorders;\n* Pregnant or lactating, or unable to comply with contraceptives within 6 months after end of study;\n* Have participated in other clinical trials within 12 weeks before the screening;\n* Severe and poorly controlled comorbidities;","65 Years",{"count":126,"type":23},162,[26,80],"This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It contains two parts dose-escalating, and blind random study in adult KOA subjects.",[130],"Knee Osteoarthritis",[29,132],"Mesenchymal Stromal Cells","2024-12-16",{"date":135,"type":36},"2024-12-18",{"date":137,"type":23},"2025-02-20",{"date":139,"type":23},"2028-11-15",{"name":42,"class":43},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":51,"minAge":76,"maxAge":124,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100549978","phase-1-a-trial-to-evaluate-the-safety-and-efficacy-of-ncr300-in-preventing-recurrence-of-acute-myeloid-leukemiaaml-after-transplantation-100549978","NCT06441084","A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation","A Phase I or II Clinical Trial Evaluating the Safety and Efficacy of NCR300 Injection in Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation","Inclusion Criteria:\n\n1.Subjects who understand and voluntarily sign the Informed Consent Form(ICF);\n\n2.18-65years;\n\n3.Clinical diagnosis of AML;\n\n4.Accepted allogeneic blood stem cell transplantation within 60 to 28 days prior before initial infusion;\n\n5.Complete donor chimerism and with high-risk recurrence factors prior to transplantation , or bone marrow examination shows positive MRD；\n\n6.Have already recovered from the adverse reactions of previous treatment；\n\n7.Having appropriate organ functions；\n\n8.Eastern Cooperative Oncology Group(ECOG)\\\u003C3;\n\n9.Subjects who are able to comply with contraceptives from the study period to 6 months after the end of this study;\n\nExclusion Criteria:\n\n1. Bone marrow examination shows hematological recurrence;\n2. Have malignant tumors within 5 years before screening;\n3. Subjects with acute promyelocytic leukemia(APL);\n4. Subjects with severe respiratory diseases;\n5. Subjects with clear history of neurological or psychiatric disorders in the past;\n6. Active central nervous system involvement；\n7. HIV(human immunodeficiency virus) antibody positive,treponema pallidum(TP) antibody positive.Have active hepatitis B or hepatitis C;\n8. Allergies to NCR300 or its excipients;\n9. Subjects with active cardiovascular and cerebrovascular diseases;\n10. Received organ transplantation or planned transplantation；\n11. Received other treatment drugs after transplantation；\n12. Graft-Versus-Host Disease (GVHD)\\>II grades;\n13. Subjects with active nervous system autoimmune or inflammatory diseases;\n14. Expected survival period within 3 months;\n15. Have alcohol or drug addiction or with a clear history of mental disorders or with a history of drug abuse or drug use of psychotropic substances;\n16. Having mental illness；\n17. Having uncontrollable active infections;\n18. Subjects whose state is not suitable for entering the study;\n19. Other situations determined by investigator that it is not suitable to enter the study.",{"count":149,"type":23},15,[26],"A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.",[153],"Acute Myeloid Leukemia",[155],"iNK","2024-06-02",{"date":158,"type":36},"2024-06-04",{"date":160,"type":23},"2024-06-30",{"date":162,"type":23},"2031-12-31",{"name":42,"class":43},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":51,"minAge":76,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":173,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100534914","a-trial-to-evaluate-the-safety-and-preliminary-efficacy-of-ink-in-the-treatment-of-subjects-with-solid-tumor-100534914","NCT06245018","A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor","An Open, Dose Escalation and Extension Platform Trial to Evaluate the Safety, Pharmacological and Preliminary Efficacy of Human Induced Pluripotent Stem Cell Derived Natural Killer Cells (iNK) in Chinese Subjects With Solid Tumor","Inclusion Criteria:\n\n1. ≥18 years old.\n2. Subjects with recurrent or metastatic solid tumors that cannot accept radical locoregional therapy;\n3. Systemic standard treatment failed or cannot tolerate serious toxicity or lack of standard treatment.\n4. Have 1 or more focus can be accessed according to RECIST 1.1\n5. Eastern Cooperative Oncology Group(ECOG):0-1\n6. Expected survival period over 3 months\n7. Have acceptable organ function and the results of laboratory examination meet the request below:\n\n   Hepatic Insufficiency (ALT) and Aspartate aminotransferase（AST）≤3xULN(upper limit of normal);Total Bilirubin≤3xULN；Creatinine≤3xULN；White blood cell count ≥3.0x10\\^9\u002FL; Absolute Neutrophil Count≥1.0x10\\^9\u002FL\n8. Agree to contraception\n9. Subjects who understand and voluntarily sign the Informed Consent Form（ICF)\n\nExclusion Criteria:\n\n1. Central nervous system metastasis or meningeal metastasis with clinical symptoms；\n2. With active infection during screening\n3. Have serious or uncontrolled basic diseases;\n4. Have continuous adverse event caused by previous anti-tumor therapy that might affect the evaluation of drug safety；\n5. Accept anti-tumor therapy within 28 days before first injection;\n6. Accept general anesthesia surgery or radiation therapy within 28 days before first injection;\n7. Accept live vaccine or attenuated live vaccine within 28 days before first injection;\n8. Allergy to known drug components;\n9. Serous cavity effusion requiring clinical intervention；\n10. Pregnancy or prepare to pregnant during the treatment;\n11. Other situations that not suitable to participate into this trial.",{"count":172,"type":23},50,[174],"NA","This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.",[177],"Solid Tumor",[155],"2024-01-29",{"date":181,"type":36},"2024-02-07",{"date":183,"type":23},"2024-02-01",{"date":185,"type":23},"2030-03-01",{"name":42,"class":43},""]